ISMMS CTSA, ConduITS Evaluation and Continuous Improvement (ECI) Core

Sep 30, 2020 | Conduits News

The mission of the ISMMS CTSA, ConduITS, is to streamline and centralize the infrastructure needed to accelerate translational research across an ever expanding research enterprise; foster team science responsive to emerging theories, technologies, and data science challenges; innovate processes to increase the quality and efficiency of translational research; develop informatics tools and solutions to accelerate the full translational continuum; and develop innovative educational programs training the workforce needed to respond to the challenges of 21st Century translational science.

In order to maximize the CTSA Program consortium’s impact, NCATS has implemented the Common Metrics Initiative (CMI). The CMI is based on the principles of the Results-Based Accountability (RBA) framework and is a collaborative process with the CTSA Program hubs used to develop, implement and report on specific metrics that are common across the consortium. The vision for NCATS’ CMI is to use specific, common metrics to demonstrate and improve the impact of the CTSA Program. The CMI uses this set of metrics to help focus network and hub activities on making significant, measurable improvements in translational science and research, and workforce development.

The Evaluation and Continuous Improvement (ECI) core at Mount Sinai, led by Brian Nickerson, PhD and Layla Fattah, MEd, was implemented to create an overall strategy for evaluation across the ConduITS cores. The ECI team engages with a mix of stakeholders to advance the development and implementation of innovative solutions to meet the strategic goals of our CTSA grant. Pursuant to this role, the ECI team collaborates with ConduITS leaders by utilizing evaluation activities and methods that range from fundamental assessment techniques to emerging cutting-edge methods and metrics. As internal evaluators, the team works across the Cores to develop relevant and useful metrics for examining innovation impact and continuous improvement activities. In addition, the ECI is uniquely situated to interpret and connect the national CTSA common metrics locally in efforts towards improvement and innovation.

ConduITS is supported by NCATS of the NIH’s CTSA Program. Any use of CTSA-supported resources requires citation of grant number UL1TR001433 awarded to ISMMS in the acknowledgment section of every publication resulting from this support. Adherence to the NIH Public Access Policy is also required.

 

 

Recent ConduITS News

Introduction to the Research Roadmap

Who Should Use the Research Roadmap at Mount Sinai? Researchers, research teams, and trainees within the Mount Sinai Health System (MSHS), including any research professional at the Icahn School of Medicine at Mount Sinai (ISMMS).  What is the Research Roadmap? The...

read more

Introduction to ResearchMatch

What is ResearchMatch? ResearchMatch is a nonprofit, online recruitment platform designed to connect researchers with volunteers interested in participating in health-related research studies. It allows researchers to efficiently find eligible participants while...

read more

Introduction to Oncore

OnCore is Mount Sinai’s Clinical Trials Management System (CTMS), that is designed to support the full lifecycle of research studies. It helps teams manage protocols, track enrollment and oversee finances —all through integrated tools and automated workflows.  Mount...

read more

Trainee Corner

Mount Sinai CTSA Featured Trainees

Dr. Lee 2025 KL2 Scholar

Dr. Lee 2025 KL2 Scholar

Dr. Lee is an Assistant Professor in the Division of Surgical Oncology. Her proposal is titled ‘Generating a Multimodal Machine Learning Model for Prediction of Thyroid Cancer Recurrence’. Her mentors will be: Girish Nadkarni, MD, MPH, Michael Marin, MD, and Gerald...

read more
Dr. Xiaoqi 2025 KL2 Scholar

Dr. Xiaoqi 2025 KL2 Scholar

Dr. Xiaoqi is an Assistant Professor in the Department of Immunology and Immunotherapy. His proposal is titled ‘Nanoparticle STING Immunotherapy Against TP53-Mutated Acute Myeloid Leukemia’. His mentors will be: Brian Brown, PhD, and Joshua Brody, MD.  Dr. Xiaoqi is...

read more